Clinical Trials Logo

Rectal Cancer clinical trials

View clinical trials related to Rectal Cancer.

Filter by:

NCT ID: NCT04134897 Enrolling by invitation - Rectal Cancer Clinical Trials

Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer

RuCorT-02
Start date: October 14, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether 3 months of neoadjuvant CapOx is non-inferior to neoadjuvant radiotherapy in patients with moderate risk CRM"-" mid rectal cancer.

NCT ID: NCT04127734 Not yet recruiting - Rectal Cancer Clinical Trials

Treatment of Anastomotic Leakage After Rectal Cancer Resection

TENTACLE:R
Start date: April 1, 2020
Phase:
Study type: Observational

The TENTACLE: Rectum study is a multinational retrospective cohort study that includes patients with anastomotic leakage after rectal cancer resection. The study aims to develop an anastomotic leakage severity score and to evaluate the efficacy of different treatments of anastomotic leakage.

NCT ID: NCT04124601 Completed - Rectal Cancer Clinical Trials

Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer

CHINOREC
Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab and nivolumab in rectal cancer.

NCT ID: NCT04109755 Recruiting - Rectal Cancer Clinical Trials

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

PEMREC
Start date: June 2, 2020
Phase: Phase 2
Study type: Interventional

This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS) rectal cancer.

NCT ID: NCT04108481 Suspended - Rectal Cancer Clinical Trials

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

iRE-C
Start date: October 5, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).

NCT ID: NCT04103697 Enrolling by invitation - Rectal Cancer Clinical Trials

Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer

RuCorT-01
Start date: August 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether 4 cycles of neoadjuvant CapOx chemotherapy is more effective than the upfront surgery in patients with intermediate risk CRM"-" mid and upper rectal cancer.

NCT ID: NCT04103567 Recruiting - Rectal Cancer Clinical Trials

Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Treatment in Rectal Cancers

MICARE
Start date: January 14, 2020
Phase: N/A
Study type: Interventional

The objective of this project is to determine in a non-invasive manner (fecal samples) the predictive value of the intestinal microbiota and the presence of genotoxin-producing bacteria on the response to neoadjuvant treatment in rectal cancer. This could lead to a better understanding and selection of patients for personalized treatment in rectal cancer.

NCT ID: NCT04103372 Not yet recruiting - Rectal Cancer Clinical Trials

Pre-therapeutic MRI Assessment of Early Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery: A New Approach to the Management of Early Stage Rectal Cancer.

PRESERVE
Start date: November 2019
Phase: N/A
Study type: Interventional

This multicentre, prospective, randomised, feasibility trial aims to change UK practice by enabling more patients with early rectal cancer to safely undergo local excision rather than major surgery thus maintaining quality of life without compromising survival outcomes.

NCT ID: NCT04098471 Not yet recruiting - Rectal Cancer Clinical Trials

Simple Transanal Local Excision,Transanal Local Excision Following Radiotherapy Versus Total Mesorectum Excision for the Treatment of the Ultra-low T2N0M0 Rectal Cancer

Start date: December 2019
Phase: N/A
Study type: Interventional

A randomized controlled clinical trial to compare the short and long term outcomes of simple transanal local excision,transanal local excision following radiotherapy or total mesorectal excision for the treatment of Rectal Cancer

NCT ID: NCT04096118 Completed - Rectal Cancer Clinical Trials

Relationship Between Lymph Node Ratio and Survival Rate in Preoperative Chemoradiation Rectal Cancer Patients

Start date: April 1, 2018
Phase:
Study type: Observational

Colorectal cancer is the most-common cancer of the gastrointestinal tract. The number of positive lymph nodes and total number of lymph nodes retrieved are important prognostic factors. In patients who do not receive preoperative chemoradiation, the total number of lymph nodes should be more than 12 nodes to predict accurate staging. In cases of locally-advanced rectal cancer when patients receive neoadjuvant chemoradiation it is sometimes impossible to retrieve adequate amount of lymph nodes due to the chemoradiation effect. Therefore, this study was to evaluate and predict survival rates based on positive lymph node ratio.